Merck Animal Health has acquired a controlling stake in Vallée S.A.
Merck Animal Health has acquired a controlling stake in Vallée S.A.
Merck Animal Health, known as MSD outside the USA and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.
Vallée was founded in 1961 in Uberlândia, State of Minas Gerais, as a company dedicated to the production of vaccines for foot-and-mouth disease. Vallée is one of the largest animal health companies in Brazil, with a diversified product offering, including vaccines, antiparasiticides, supplements, therapeutic, reproduction and nutritional products for both production animals and pets.
One of Oaklins’ teams in Brazil acted as the sole financial advisor for Merck Animal Health in this transaction.
Talk to the deal team
Richard Rainer
Oaklins Olimpia Partners
Related deals
Kaviari has received a minority investment from idiCo
Kaviari has received a minority investment from a pool of investors led by idiCo, alongside Bpifrance, IRD Invest and UI Investissement.
Learn moreAWC has acquired a significant minority stake in MyFitness
AWC AS, the investment company of the Norwegian family office Awilhelmsen, has acquired a 22.2% stake in MyFitness AS, the largest fitness club operator in the Baltics, becoming the MyFitness’ largest single shareholder.
Learn moreInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn more